SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present at two upcoming investor conferences scheduled to take place in March 2023.
Details of the presentations appear below:
Conference: 35th Annual Roth Conference
Date: Tuesday, March 14, 2023
Time: 10:00am PDT
Location: Dana Point, CA
Format: Fireside Chat
Conference: Oppenheimer 33rd Annual Healthcare Conference
Date: Wednesday, March 15, 2023
Time: 10:00am EDT
Location: Virtual
Format: Corporate Presentation
In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. A webcast and replay of the Corporate Presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com. For more information, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..
About aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit www.atyrpharma.com.
Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.75 |
| Daily Change: | 0.05 6.67 |
| Daily Volume: | 10,504,779 |
| Market Cap: | US$73.490M |
September 30, 2025 September 15, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
